Premium
Biogenic ( R )‐(+)‐Lipoic Acid Only Constructed Cross‐Linked Vesicles with Synergistic Anticancer Potency
Author(s) -
Liao Chunyan,
Dai Xin,
Chen Ying,
Liu Jie,
Yao Yongchao,
Zhang Shiyong
Publication year - 2019
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.201806567
Subject(s) - potency , lipoic acid , in vivo , drug delivery , pharmacology , drug , cancer chemotherapy , in vitro , nanotechnology , materials science , biochemistry , chemotherapy , chemistry , biology , medicine , microbiology and biotechnology , antioxidant
Although the drug delivery systems (DDSs) hold great potential for cancer chemotherapy, the drug carriers themselves become redundant substances in the body, once the delivering task is finished. They not only have no therapeutic effect, but even can sometimes cause unexpectedly toxic and side effects, which confine seriously the clinical prospect of DDSs. Herein, a new drug container of cross‐linked lipoic acid vesicles (cLAVs) constructed solely by biogenic ( R )‐(+)‐lipoic acid (LA) is developed. Benefited from the structure homology with LA, the cLAVs are no longer the redundant substances after drug delivery, but LA‐like “vitamins” with strong synergistic anticancer potency both in vitro and in vivo, and, thus represent a particularly powerful carrier for cancer chemotherapy.